Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1509-1520

  Sun, Ying ^a   Li, Wen Fei ^a   Chen, Nian Yong ^b   Zhang, Ning ^c   Hu, Guo Qing ^d   Xie, Fang Yun ^a   Sun, Yan ^e   Chen, Xiao Zhong ^f   Li, Jin Gao ^g   Zhu, Xiao Dong ^h   Hu, Chao Su ⁱ   Xu, Xiang Ying ^j   Chen, Yuan Yuan ^f   Hu, Wei Han ^a   Guo, Ling ^a   Mo, Hao Yuan ^a   Chen, Lei ^a   Mao, Yan Ping ^a   Sun, Rui ^a   Ai, Ping ^b   Liang, Shao Bo ^c   Long, Guo Xian ^d   Zheng, Bao Min ^e   Feng, Xing Lai ^f   Gong, Xiao Chang ^g   Li, Ling ^h   Shen, Chun Ying ⁱ   Xu, Jian Yu ^j   Guo, Ying ^a   Chen, Yu Ming ^k   Zhang, Fan ^a   Lin, Li ^a   Tang, Ling Long ^a   Liu, Meng Zhong ^a   Ma, Jun ^a   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SICHUAN UNIVERSITY   (China)

^c THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^d TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^f ZHEJIANG CANCER HOSPITAL   (China)

^g JIANGXI CANCER HOSPITAL   (China)

^h GUANGXI MEDICAL UNIVERSITY   (China)

ⁱ FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^j HARBIN MEDICAL UNIVERSITY   (China)

^k SUN YAT SEN UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHINA; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DERMATITIS; DYSPHAGIA; ESOPHAGITIS; FAILURE FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ODYNOPHAGIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA; ADVERSE EFFECTS; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; TAXOIDS;

EID: 84995610406     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30410-7     Document Type: Article

References (34)

1. 1 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Mao, YP, Xie, FY, Liu, LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys 73 (2009), 1326–1334.
3. 3 Lai, SZ, Li, WF, Chen, L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?. Int J Radiat Oncol Biol Phys 80 (2011), 661–668.
4. 4 Chen, L, Hu, CS, Chen, XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13 (2012), 163–171.
5. 5 Cvitkovic, E, Eschwege, F, Rahal, M, et al. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35 (1996), 463–469.
6. 6 Chua, DT, Sham, JS, Choy, D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 83 (1998), 2270–2283.
7. 7 Ma, J, Mai, HQ, Hong, MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 19 (2001), 1350–1357.
8. 8 Hareyama, M, Sakata, K, Shirato, H, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94 (2002), 2217–2223.
9. 9 Vermorken, JB, Remenar, E, van Herpen, C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 (2007), 1695–1704.
10. 10 Posner, MR, Hershock, DM, Blajman, CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007), 1705–1715.
11. 11 Pointreau, Y, Garaud, P, Chapet, S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101 (2009), 498–506.
12. 12 Zhang, QH, Luo, W, Zhou, QC, Yu, Z, Ma, J, Liu, MZ, TPF induction chemotherapy followed by intensity-modulated radiotherapy and concomitant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer Prev Treat 16 (2009), 625–628.
13. 13 Guo, L, Lin, HX, Xu, M, Chen, QY, Wang, CT, Huang, PY, Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer 29 (2010), 136–139.
14. 14 Bae, WK, Hwang, JE, Shim, HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 65 (2010), 589–595.
15. 15 Du, C, Ying, H, Zhou, J, Hu, C, Zhang, Y, Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Int J Clin Oncol 18 (2013), 464–471.
16. 16 Kong, L, Hu, C, Niu, X, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials. Cancer 119 (2013), 4111–4118.
17. 17 Xiao, WW, Huang, SM, Han, F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 117 (2011), 1874–1883.
18. 18 Lee, N, Xia, P, Quivey, JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 (2002), 12–22.
19. 19 Kam, MK, Teo, PM, Chau, RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60 (2004), 1440–1450.
20. 20 Wolden, SL, Chen, WC, Pfister, DG, Kraus, DH, Berry, SL, Zelefsky, MJ, Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64 (2006), 57–62.
21. 21 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
22. 22 Cox, JD, Stetz, J, Pajak, TF, Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995), 1341–1346.
23. 23 Hui, EP, Ma, BB, Leung, SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27 (2009), 242–249.
24. 24 Chow, SC, Shao, J, Wang, H, Sample size calculations in clinical research, 2003, Marcel Dekker, New York.
25. 25 Pocock, SJ, Clayton, TC, Altman, DG, Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359 (2002), 1686–1689.
26. 26 Cox, DR, Regression models and life tables. J R Stat Soc B 34 (1972), 187–220.
27. 27 Schoenfeld, D, Partial residuals for the proportional hazards regression model. Biometrika 69 (1982), 239–241.
28. 28 Fountzilas, G, Ciuleanu, E, Bobos, M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol 23 (2012), 427–435.
29. 29 Tan, T, Lim, WT, Fong, KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 91 (2015), 952–960.
30. 30 Lee, AW, Tung, SY, Ngan, RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer 47 (2011), 656–666.
31. 31 Loong, HH, Ma, BB, Leung, SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 104 (2012), 300–304.
32. 32 Chan, AT, Teo, PM, Ngan, RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (2002), 2038–2044.
33. 33 Lee, AW, Lau, WH, Tung, SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (2005), 6966–6975.
34. 34 Lin, JC, Wang, WY, Chen, KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350 (2004), 2461–2470.